Nonsecretory multiple myeloma (NSMM) is the variant of multiple myeloma defined by no detectable M protein secretion in serum or urine electrophoresis. Due to the lack of detectable M spike, diagnosis is often challenging and relies on bone marrow studies. As studies specifically focusing on NSMM are lacking, the current treatment guidelines are based on studies in secretory multiple myeloma. In this case report, we describe a 77-year-old female patient with a typical presentation of NSMM who did not respond to a chemotherapy regimen based on daratumumab.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891464 | PMC |
| http://dx.doi.org/10.7759/cureus.78665 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spleen Involvement at Diagnosis of Multiple Myeloma: A Case Report and Literature Review.
Cancer Rep (Hoboken)
March 2025
UOC Haematology, ASL Viterbo-Santa Rosa Hospital, Viterbo, Italy.
Background: Multiple myeloma (MM) is more often characterized by clonal plasma cell proliferation restricted to the bone marrow. However, a small percentage of patients with MM develop extramedullary disease (EMD): this type of localization is found in 1.7%-4.
View Article and Find Full Text PDFPlasma Cell-Rich Lymphoid Neoplasm in an Endocervical Polyp of the Uterine Cervix in a Perimenopausal 52-Year-Old Woman.
HCA Healthc J Med
February 2025
St David's North Austin Medical Center, Austin, Texas.
Background: The adaptive immune system consists of T and B lymphocytes, with some B lymphocytes further differentiating into plasma cells that secrete antibodies and make up the humoral immune system. Extramedullary plasmacytoma, mucosa-associated lymphoid tissue (MALT) lymphoma, and plasmablastic lymphoma are all plasma cell-rich lymphoid neoplasms that rarely present in the female genital tract. To date, few case reports of these malignancies arising within the uterine cervix exist.
View Article and Find Full Text PDFPlasmaCell CAD: A computer-aided diagnosis software tool for plasma cell recognition and characterization in microscopic images.
Int J Med Inform
March 2025
Department of Bioelectrics and Biomedical Engineering, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan 81746, Iran; Medical Image & Signal Processing Research Center, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan 81746, Iran. Electronic address:
Background And Objective: In the traditional diagnostic process for multiple myeloma cancer, a pathologist screens prepared blood samples using a microscope to detect, classify, and count plasma cells. This manual approach is time-consuming, exhausting, and prone to human errors. Consequently, medical experts and researchers are highly interested in any tool that partially or entirely automates this process.
View Article and Find Full Text PDFComprehensive bioinformatics analysis reveals key hub genes linked to prognosis in multiple myeloma with drug resistance.
Medicine (Baltimore)
March 2025
Department of Laboratory Medicine, Rongcheng District Central Hospital, Jieyang, China.
Multiple myeloma (MM) is an incurable hematologic malignancy, with chemotherapy being the primary treatment. However, the development of drug resistance remains a major challenge. This study aimed to identify therapeutic targets associated with drug resistance in MM and assess their prognostic significance.
View Article and Find Full Text PDFIndium-111-Labeled Single-Domain Antibody for CXCR4 Imaging Using Single-Photon Emission Computed Tomography.
Bioconjug Chem
March 2025
Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven 3000, Belgium.
C-X-C chemokine receptor type 4 (CXCR4) is highly expressed in a range of pathologies, including cancers like multiple myeloma and non-Hodgkin lymphoma, inflammatory diseases such as rheumatoid arthritis, and viral infections like HIV. Currently, the most advanced radiotracer for CXCR4 imaging in clinics is [Ga]PentixaFor. However, its structure is prone to modifications, complicating the development of a specific CXCR4 fluorine-18-labeled tracer with good pharmacokinetic properties.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!